Chemical compound
Pharmaceutical compound
Fasedienol Other names PH94B; Aloradine; 4-Androstadienol; 3β-Androsta-4,16-dien-3-ol, Androsta-4,16-dien-3β-ol; Androstadienol Routes of Intranasal ATC code
(3S ,8S ,9S ,10R ,13R ,14S )-10,13-Dimethyl-2,3,6,7,8,9,11,12,14,15-decahydro-1H -cyclopenta[a]phenanthren-3-ol
CAS Number PubChem CID DrugBank ChemSpider UNII KEGG CompTox Dashboard (EPA ) Formula C 19 H 28 O Molar mass −1 3D model (JSmol )
C[C@]12CC[C@H]3[C@H]([C@@H]1CC=C2)CCC4=C[C@H](CC[C@]34C)O
InChI=1S/C19H28O/c1-18-9-3-4-16(18)15-6-5-13-12-14(20)7-11-19(13,2)17(15)8-10-18/h3,9,12,14-17,20H,4-8,10-11H2,1-2H3/t14-,15-,16-,17-,18-,19-/m0/s1
Key:NYVFCEPOUVGTNP-DYKIIFRCSA-N
Fasedienol (INN Tooltip International Nonproprietary Name ; developmental code names PH94B and Aloradine ), also known as 4-androstadienol or as 4,16-androstadien-3β-ol , is a pherine which is under development by VistaGen Therapeutics[ 1] [ 2] nasal spray formulation (PRN social anxiety disorder .[ 3] [ 4] [ 5] [ 6] [ 7] [ 8] [ 9] generalized anxiety disorder (GAD) and post-traumatic stress disorder (PTSD).[ 10] [ 11] positional isomer of the endogenous pheromone androstadienol (5-androstadienol or 5,16-androstadien-3β-ol). As of 2020, it is in phase III clinical trials for social anxiety disorder. [ 12]
Fasedienol lacks affinity for steroid hormone receptors and has instead been found to directly activate isolated human vomeronasal receptor cells at nanomolar concentrations (EC50 = 200 nM).[ 8]
The closely related pheromone androstenol (5α-androst-16-en-3α-ol) has been found to act as a potent positive allosteric modulator of the GABAA receptor , and it has been proposed that this action may mediate its pheromone effects.[ 13] anxiolytic -like effects in animals.[ 13] Androstadienol , androstadienone , and androstenone , all of which are also pheromones, have been found to be converted into androstenol, and as such, it may be responsible for their pheromone effects.[ 13] A receptor could contribute to its mechanism of action.[ 13]
See also
References
^ "VistaGen Therapeutics Acquires Worldwide License of Phase 3-Ready CNS Drug Candidate from Pherin Pharmaceuticals for As-Needed Treatment of Social Anxiety Disorder :: VistaGen Therapeutics, Inc. (VTGN)" . VistaGen Therapeutics, Inc . Archived from the original on 2019-12-19. Retrieved 2019-12-19 .^ Al Idrus A (13 September 2018). "VistaGen nabs phase 3-ready social anxiety drug from Pherin" . FierceBiotech . Retrieved 2019-12-19 . ^ Murphy J (10 December 2019). "FDA Grants Fast Track Designation to PH94B for Treatment of Social Anxiety Disorder" . Pharmacy Times . Retrieved 2019-12-19 . ^ Griebel G, Holmes A (September 2013). "50 years of hurdles and hope in anxiolytic drug discovery" (PDF) . Nature Reviews. Drug Discovery . 12 (9): 667– 87. doi :10.1038/nrd4075 . PMC 4176700 PMID 23989795 . ^ Monti-Bloch L, Jennings-White C, Dolberg DS, Berliner DL (1994). "The human vomeronasal system". Psychoneuroendocrinology . 19 (5– 7): 673– 86. doi :10.1016/0306-4530(94)90049-3 . PMID 7938363 . S2CID 36129626 . ^ Rolls ET (November 2013). Emotion and Decision Making Explained ISBN 978-0-19-965989-0 ^ BioScan ^ a b Liebowitz MR, Salman E, Nicolini H, Rosenthal N, Hanover R, Monti L (June 2014). "Effect of an acute intranasal aerosol dose of PH94B on social and performance anxiety in women with social anxiety disorder" . The American Journal of Psychiatry . 171 (6): 675– 82. doi :10.1176/appi.ajp.2014.12101342 . PMID 24700254 . S2CID 38510058 . ^ US patent 8722652 , Louis Monti-Bloch, "Acute Treatment of Social Phobia", published 13 November 2012, assigned to Pherin Pharmaceuticals, Inc. ^ "Generalized Anxiety Disorder :: VistaGen Therapeutics, Inc. (VTGN)" . VistaGen Therapeutics, Inc . Archived from the original on 2019-12-19. Retrieved 2019-12-19 .^ "Post-traumatic Stress Disorder :: VistaGen Therapeutics, Inc. (VTGN)" . VistaGen Therapeutics, Inc . Retrieved 2019-12-19 .^ "Positive Pilot Phase 3 Data Position VistaGen's PH94B Neuroactive Nasal Spray for Pivotal Phase 3 Development as a Novel, As-Needed Treatment for Social Anxiety Disorder :: VistaGen Therapeutics, Inc. (VTGN)" . VistaGen Therapeutics, Inc . Archived from the original on 2019-12-19. Retrieved 2019-12-19 .^ a b c d Kaminski RM, Marini H, Ortinski PI, Vicini S, Rogawski MA (May 2006). "The pheromone androstenol (5 alpha-androst-16-en-3 alpha-ol) is a neurosteroid positive modulator of GABAA receptors". The Journal of Pharmacology and Experimental Therapeutics . 317 (2): 694– 703. doi :10.1124/jpet.105.098319 . PMID 16415088 . S2CID 95393004 .
External links
